Publication: American Journal of Veterinary Research
Abstract
Phenylbutazone is a commonly used equine anti-inflammatory drug, but its pharmacokinetics in geriatric horses had not been well characterized despite the potential for age-related changes in drug disposition. This study compared phenylbutazone and its active metabolite oxyphenbutazone following a single intravenous dose in eight young-adult and eight geriatric horses, with pharmacokinetic parameters calculated using Phoenix WinNonlin. No significant differences in phenylbutazone or oxyphenbutazone pharmacokinetic parameters were found between age groups, despite a two-compartment model best describing drug disposition in both. The findings do not support the need for phenylbutazone dose adjustments in clinically healthy geriatric horses compared with younger adults.
Author(s): Zaghloul IY, Bedenice D, Ceresia ML, Jones PH, Sanchez‑Londono A, Lobo MN, Böhlke M, Paradis MR
Published: June 28, 2024
Phoenix WinNonlin: Age Comparison in Veterinary PK
Phoenix WinNonlin’s two-compartment modeling found no meaningful pharmacokinetic differences between young and geriatric horses in this equine anti-inflammatory study. As part of a Phoenix platform built on a validated, secure foundation, Phoenix WinNonlin’s results can flow directly into PK Submit for CDISC-compliant submission packages.
